ADHD drug gets three more dosage strengths
Shire's ADHD treatment lisdexamfetamine (Vyvanse) was approved by the FDA in three new dosage strengths. The current 30 mg-, 50 mg and 70 mg-dosage strengths will be joined by 20 mg-, 40 mg-, and 60 mg-dosage strengths. They will be available in the second quarter of this year.
Lisdexamfetamine is approved to treat ADHD in children between 6 and 12 years of age. Many who receive treatment have their dose levels titrated up or down. These additional dosage strengths could offer a more gradual process in titrating, 10 mg at a time.
New research finds significant challenges for children with disabilities in foster care
September 27th 2024A study presented at the American Academy of Pediatrics 2024 National Conference finds children with disabilities in foster care face lower permanency rates and higher mortality risks, calling for specialized support and interventions.
